OakChart

Daxor Corp

DXRHealthcare·Medical Instruments & Supplies·USA·Nano·NASD·Nov 11 • 3:59 PM ET

8.43-0.10 (-1.17%)
2026-11-11 22:02 CET
Market cap
49.80 USD m
Revenue, TTM
0.15 USD m
Net income, TTM
6.23 USD m
Free cash flow, TTM
-2.81 USD m
EPS diluted, TTM
1.22
P/E
6.90
Compare

Price

DXR against its 20, 50 and 200-day averages
2050200
9.0010.0011.0012.00101K201KVolumeApr 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DXRclose 8.4320-day 9.1450-day 10.20200-day 10.708.43

42.9% under the 52-week high of 14.76 on 29 Dec 2025. 52-week low 8.40 on 30 Oct 2026. Last 15 sessions, 17.4% high to low

Volume 0.16× normal · the line is the 50-bar volume average

Profile

DXR
52-week range, 0% of the way up
8.4014.76

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

IPOJul 25, 1983
Beta0.45
ATR, 14d0.41
Rel volume0.16
Short float0.03%
Insider own49.20%
Inst own7.96%

Snapshot

6 groups

Valuation

Index-
Market Cap49.23M
Enterprise Value43.44M
Income6.23M
Sales0.15M
Book/sh8.88
Cash/sh0.99
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJan 05, 2018
Dividend Gr. 3/5Y- -
Payout0.00%
Employees-
IPOJul 25, 1983

Ratios

P/E6.90
Forward P/E-
PEG-
P/S328.21
P/B0.95
P/C8.50
P/FCF-
EV/EBITDA6.97
EV/Sales289.61
Quick Ratio245.27
Current Ratio245.27
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)1.22
EPS next Y-0.03
EPS next Q-0.04
EPS this Y-320.00%
EPS next Y85.71%
EPS next 5Y-
EPS past 3/5Y13.20% -
Sales past 3/5Y- -
EPS Y/Y TTM234.88%
Sales Y/Y TTM-85.48%
EPS Q/Q-791.41%
Sales Q/Q-93.80%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own49.20%
Insider Trans0.00%
Inst Own7.96%
Inst Trans-0.02%
ROA14.20%
ROE14.24%
ROIC12.02%
Gross Margin-106.52%
Oper. Margin4024.05%
Profit Margin4021.89%
SMA20-7.78%
SMA50-17.32%
SMA200-21.18%
Trades-

Technical

Shs Outstand5.84M
Shs Float2.97M
Short Float0.03%
Short Ratio0.05
Short Interest0.00M
52W High14.76 -42.88%
52W Low8.40 0.36%
Volatility4.01% 4.11%
ATR (14)0.41
RSI (14)32.26
Beta0.45
Rel Volume0.16
Avg Volume22.16K
Volume3,585

Performance

Perf Week-5.41%
Perf Month-18.55%
Perf Quarter-18.94%
Perf Half Y-19.71%
Perf YTD-42.85%
Perf Year-34.14%
Perf 3Y8.08%
Perf 5Y-22.09%
Perf 10Y6.31%
Recom1.00
Target Price20.00
Prev Close8.53
Price8.43
Change %-1.17%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
May 16, 2019InitiatedAAscendiant Capital MarketsBuy$20+137.2%

Peers

Mkt cap
TickerCompanyMkt cap
UTMDUtah Medical Products Inc208.06M
HAEHaemonetics Corp5.49B
LMATLemaitre Vascular Inc1.81B
CVRXCVRx Inc19.95M
CTSOCytosorbents Corp16.83M
NUWENuwellis Inc2.99M
ELMDElectromed Inc206.68M
HSCSHeartSciences Inc11.40M
IRMDIradimed Corp1.11B
BJDXBluejay Diagnostics Inc3.13M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Feldschuh Michael RichardChief Executive OfficerApr 08 '26Buy9.071,0009,070213,694Apr 10 01:54 PM
Michel Robert JChief Financial OfficerMar 31 '26Buy9.901,0009,90021,050Mar 31 06:28 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 200
  • Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26 (GlobeNewswire)
  • Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026 (GlobeNewswire)
  • Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026 (GlobeNewswire)
  • Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 (GlobeNewswire)
  • Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference (GlobeNewswire)
  • Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter (GlobeNewswire) +8.14%
  • Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas (GlobeNewswire)
  • Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas (GlobeNewswire)
  • Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor (GlobeNewswire)
  • Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis (GlobeNewswire) +5.39%
  • Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center (GlobeNewswire)
  • Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 (GlobeNewswire)
  • Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions (GlobeNewswire)
  • Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024S12024-08-30-0.390--1.00--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-0.050-0.040-6.707.00
2026FY--0.210--9.30
2027FY--0.030--16.40

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYS2026-09-011019.309.309.30
2026FYS2026-02-2610011.9011.9011.90
2026FYS2026-02-1010011.9011.9011.90
2026FYE2026-02-26100-0.21-0.21-0.21
2026FYE2026-02-10100-0.21-0.21-0.21

Estimate history

EPS, annual-0.329-0.237-0.132-0.4331.1761.2680.0610.1111.839
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual-1.461-1.3081.741-2.806-2.615-0.35334.59-0.1360.503
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual3.7373.7473.7474.0344.0394.2914.8064.9345.06
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.150.50-0.1434.59-0.35-2.62-2.811.74-1.31
Total Expenses-6.08-8.68-0.7634.26-5.60-7.38-1.082.24-0.09
Operating Income6.239.190.620.335.254.77-1.72-0.50-1.22
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes6.239.170.540.285.184.75-1.73-0.50-1.22
Income Taxes0.000.000.000.000.000.00-0.030.00-0.33
Consolidated Net Income6.239.170.540.285.184.75-1.71-0.50-0.89
Net Income From Continuing Operations6.239.170.540.285.184.75-1.71-0.50-0.89
Net Income6.239.170.540.285.184.75-1.71-0.50-0.89
EPS (Recurring)1.251.840.110.061.271.18-0.43-0.13-0.24
EPS (Basic, Before Extraordinaries)1.221.840.110.061.271.18-0.43-0.13-0.24
EPS (Diluted)1.221.840.110.061.271.18-0.43-0.13-0.24
Non-Operating Income (Expense)0.000.000.000.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.530.771.250.630.790.730.300.200.07
Price To Earnings Ratio6.986.9821.819.278.249.59---
Price To Sales Ratio331.40146.07-1.29---20.23-
Gross Margin-106.5237.49221.5399.49407.64138.30124.4678.91120.53
Operating Margin4,024.051,824.65-458.050.95-1,485.92-182.3161.37-28.4793.17
Net Margin4,021.891,821.48-395.330.81-1,465.41-181.5660.77-28.4767.74
Shares Outstanding5.845.064.934.814.294.044.033.753.75
Market Capitalization49.8049.8037.2045.4637.0045.5248.6135.2230.58

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue0.020.130.370.70-0.8336.35-1.76-0.32
Total Expenses3.33-9.410.73-1.510.7533.291.23-7.36
Operating Income-3.319.54-0.362.21-1.583.06-2.997.04
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.319.54-0.372.17-1.633.32-3.046.99
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.319.54-0.372.17-1.633.32-3.046.99
Net Income From Continuing Operations-3.319.54-0.372.17-1.633.32-3.046.99
Net Income-3.319.54-0.372.17-1.633.32-3.046.99
EPS (Recurring)-0.661.89-0.070.44-0.340.69-0.681.72
EPS (Basic, Before Extraordinaries)-0.661.89-0.070.44-0.340.69-0.681.72
EPS (Diluted)-0.661.89-0.070.44-0.340.69-0.681.72
Non-Operating Income (Expense)0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.970.560.210.970.280.310.320.59
Price To Earnings Ratio6.9840.4496.3621.81951.029.279.278.24
Price To Sales Ratio331.40148.2445.51-1.271.33--
Gross Margin-262.06-79.3678.9589.26110.86100.01124.95324.03
Operating Margin-14,382.887,237.85-96.10317.17190.618.43169.99-2,170.64
Net Margin-14,382.887,235.32-99.49311.68196.259.13172.51-2,156.67
Shares Outstanding5.845.064.984.934.844.814.794.29
Market Capitalization49.8073.1948.5837.2045.0845.4641.1937.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments0.000.000.000.000.710.620.000.001.09
Short Term Receivables0.000.010.010.020.030.030.030.390.05
Investment Securities0.000.000.000.000.000.000.000.000.00
Securities In Custody0.000.000.000.000.000.000.000.000.00
Investments46.0036.6134.8430.2224.2215.6713.9717.2418.14
Investment in Unconsolidated Affiliates0.000.000.000.000.000.000.000.000.00
Net Property, Plant & Equipment0.000.000.000.000.000.000.000.000.00
Other Intangible Assets0.010.010.010.020.020.230.200.000.04
Total Assets46.0136.6334.8730.2624.9816.5514.2017.6319.31
Total Debt0.110.730.761.233.020.171.344.454.33
Long Term Debt0.110.730.761.233.020.171.344.454.33
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.010.110.100.060.810.710.090.111.22
Total Liabilities0.120.840.861.293.830.881.444.565.55
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity45.8935.7934.0128.9721.1515.6812.7713.0613.76
Total Shareholders Equity45.8935.7934.0128.9721.1515.6812.7713.0613.76
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity45.8935.7934.0128.9721.1515.6812.7713.0613.76
Total Liabilities & Stockholders Equity46.0136.6334.8730.2624.9816.5514.2017.6319.31
Book Value Per Share9.077.257.086.755.243.893.413.493.68
Tangible Book Value Per Share9.077.257.086.755.243.893.413.493.68
Price to Book Ratio0.961.141.521.892.153.222.762.351.18
Return on Assets22.191.500.8618.7522.86-11.09-3.11-4.80-6.21
Return on Equity22.451.540.8920.6625.79-11.99-3.84-6.61-8.52
Return on Invested Capital19.931.470.8117.1519.64-10.76-3.51-5.06-6.85
Quick Ratio0.000.090.140.280.920.922.945.390.96
Current Ratio0.000.090.140.280.920.922.945.390.96

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Funds from Operations-2.82-0.63-1.93-6.45-3.45-3.05-2.78-2.24-0.98
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.010.020.010.05-0.010.22-0.030.17-0.34
Cash from Operating Activities-2.81-0.60-1.91-6.40-3.46-2.83-2.82-2.08-1.32
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-5.371.181.942.752.690.070.375.19-
Purchase of Investments-14.600.000.000.00-0.67-0.05-17.81-2.33-
Sale Or Maturity of Investments9.221.181.942.753.360.1218.187.52-
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-5.371.181.942.752.690.070.375.190.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.440.160.004.131.850.004.240.000.11
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.03
Sale of Common Pref Stock8.440.160.004.131.850.004.240.000.14
Proceedsfrom Stock Options8.270.000.004.131.850.004.040.000.00
Issuance or Reduction of Debt, Net0.00-0.73-0.03-0.47-1.792.85-1.17-3.110.12
Change in Long Term Debt--0.73-0.03-0.47-1.792.85-1.17-3.110.12
Issuance of Long Term Debt-0.692.034.114.083.713.032.522.41
Reduction of Long Term Debt--1.42-2.05-4.59-5.87-0.86-4.20-5.63-2.29
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities8.18-0.57-0.033.660.062.853.07-3.110.23
Net Change in Cash0.000.000.000.00-0.710.090.620.00-1.09
Free Cash Flow-2.81-0.60-1.91-6.40-3.46-2.83-2.82-2.08-
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments5.790.000.000.000.000.00
Short Term Receivables0.000.000.000.010.010.01
Investments46.0046.0035.8936.6134.3634.84
Investment in Unconsolidated Affiliates0.000.000.000.000.000.00
Net Property, Plant & Equipment0.000.000.000.000.000.00
Other Intangible Assets0.070.010.010.010.010.01
Total Assets51.8646.0135.9036.6334.3834.87
Total Debt0.000.110.260.731.650.76
Long Term Debt0.000.110.260.731.650.76
Other Liabilities0.020.010.010.110.070.10
Total Liabilities0.020.120.270.841.720.86
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity51.8345.8935.6335.7932.6634.01
Total Shareholders Equity51.8345.8935.6335.7932.6634.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity51.8345.8935.6335.7932.6634.01
Total Liabilities & Stockholders Equity51.8646.0135.9036.6334.3834.87
Book Value Per Share8.889.077.157.256.757.08
Tangible Book Value Per Share8.889.077.157.256.757.08
Price to Book Ratio0.962.061.351.141.321.52
Return on Assets14.2022.195.121.505.210.86
Return on Equity14.2422.455.261.545.350.89
Return on Invested Capital-6.3920.74-1.035.93-4.759.54
Quick Ratio245.270.000.190.090.190.14
Current Ratio245.270.000.190.090.190.14

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Funds from Operations-2.41-0.41-0.21-0.54-1.39-3.90
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.100.11-0.090.04-0.030.11
Cash from Operating Activities-2.51-0.30-0.31-0.50-1.41-3.79
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-5.780.400.771.420.523.05
Purchase of Investments-14.600.000.000.000.001.64
Sale Or Maturity of Investments8.820.400.771.420.521.41
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-5.780.400.771.420.523.05
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock8.280.160.000.000.000.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock8.280.160.000.000.000.03
Proceedsfrom Stock Options8.270.000.000.000.000.03
Issuance or Reduction of Debt, Net0.00-0.26-0.47-0.920.890.76
Change in Long Term Debt--0.26-0.47-0.920.890.76
Issuance of Long Term Debt-0.180.510.551.480.78
Reduction of Long Term Debt--0.45-0.98-1.47-0.58-0.02
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.28-0.10-0.47-0.920.890.78
Net Change in Cash0.000.000.000.000.000.00
Free Cash Flow-2.51-0.30-0.31-0.50-1.41-3.79

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.03%0.0M3.0M20.97K
2026-10-150.11%0.0M3.0M19.88K
2026-09-300.23%0.0M3.0M18.05K
2026-09-150.08%0.0M3.0M11.39K
2026-08-310.02%0.0M3.0M2.52K
2026-08-140.01%0.0M3.0M2.25K
2026-07-310.01%0.0M3.0M4.39K
2026-07-150.05%0.0M3.0M5.15K
2026-06-300.04%0.0M3.0M7.73K
2026-06-150.07%0.0M3.0M8.90K
2026-05-290.21%0.0M3.0M11.30K
2026-05-150.31%0.0M3.0M11.67K
2026-04-300.12%0.0M3.0M10.31K
2026-04-150.11%0.0M3.0M10.83K
2026-03-310.11%0.0M3.0M8.92K
2026-03-130.30%0.0M3.0M7.97K
2026-02-270.12%0.0M3.0M5.34K
2026-02-130.13%0.0M3.0M5.36K
2026-01-300.27%0.0M2.5M5.01K
2026-01-150.34%0.0M2.1M4.70K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-0940-8F-2/ASEC
2026-09-24N-CEN/A2025-12-31SEC
2026-09-0440-8F-2/ASEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-31NPORT-P2026-06-30SEC
2026-08-31N-CSRCertified annual shareholder report of registered management investment companies filed on Form N-CSR2026-06-30SEC
2026-08-31N-PXAnnual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX2026-06-30SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-248-KCurrent report2026-06-23SEC
2026-06-1740-8F-2/ASEC
2026-06-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-03SEC
2026-06-02NT NPORT-P2026-03-31SEC
2026-05-2140-8F-2/ASEC
2026-05-1140-17F2Initial certificate of accounting of securities and similar investments in the custody of management investment companies filed pursuant to Rule 17f-2 of the Investment Company Act of 1940 filed on Form N-17F-2SEC
2026-05-0640-17F2Initial certificate of accounting of securities and similar investments in the custody of management investment companies filed pursuant to Rule 17f-2 of the Investment Company Act of 1940 filed on Form N-17F-2SEC
2026-04-104Statement of changes in beneficial ownership of securities2026-04-08SEC
2026-04-02N-CEN/A2025-12-31SEC
2026-03-314Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-03-3140-17F2Initial certificate of accounting of securities and similar investments in the custody of management investment companies filed pursuant to Rule 17f-2 of the Investment Company Act of 1940 filed on Form N-17F-2SEC
2026-03-244Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-03-16N-CENForm N-CEN will require annual reporting of certain census-type information in a structured XML format. Form N-CEN will replace Form N-SAR. The compliance date for Form N-CEN filers – regardless of asset size – is June 1, 2018.2025-12-31SEC
2026-03-02N-CSRCertified annual shareholder report of registered management investment companies filed on Form N-CSR2025-12-31SEC
2026-03-02NPORT-P2025-12-31SEC
2026-02-0940-8F-2Initial application for deregistration pursuant to Investment Company Act Rule 0-2SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-049.07K100
2026-039.90K100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
THOMPSON SIEGEL & WALMSLEY LLC4.14%
VANGUARD CAPITAL MANAGEMENT LLC0.84%
Aristides Capital LLC0.71%
BFC Planning, Inc.0.63%
RENAISSANCE TECHNOLOGIES LLC0.50%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.46%
NANO CAP NEW MILLENNIUM GROWTH FUND L P0.21%
Crescent Grove Advisors, LLC0.21%
BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.0.10%
SBI Securities Co., Ltd.0.05%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.84%
Gabelli Global Mini Mites Fund0.01%

OakChart. DXR. Cached 15 minutes.